Neogen Corp

Neogen Corp (NEOG) Stock Analysis

$11.790

+0.071 (+0.60%)At close

Loading chart…
High
11.915
Open
11.725
VWAP
11.80
Volume
2.12M
Mkt Cap
3.46B
Low
11.700
Amount
25.00M
EV/EBITDA, TTM
28.31

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

AI analysis of Neogen Corp (NEOG)

Buy

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, which reflects strong confidence in future performance. Additionally, the stock has shown a remarkable year-to-date change of +68.71% and a one-year change of +100.51%, indicating robust growth. However, a key risk is the current RSI of 40.44, suggesting that the stock may be approaching oversold territory, which could lead to short-term volatility.

Analyst Ratings (7)

-30.70% Downside
Hold
0 Buy
7 Hold
0 Sell
Current: 11.79
Low
6.50
Average
8.17
High
10.00

Guggenheim

2026-09-30

Price Target

$14

Buy

Guggenheim

2026-09-29

Price Target

$12

Buy

Piper Sandler

2026-08-26

Price Target

$14

Overweight

Piper Sandler

2026-08-03

Price Target

$13

Neutral

Guggenheim

2026-01-09

Price Target

$12

Buy

Valuation Metrics

The current forward P/E ratio for Neogen Corp (NEOG) is 16.00, compared to its 5-year average forward P/E of 31.34.

Forward P/E

Fair
5Y Average P/E
31.34
Current P/E
16.00
Overvalued
46.85
Undervalued
15.82

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
16.71
Current EV/EBITDA
28.31
Overvalued
25.21
Undervalued
8.21

Forward P/S

Fair
5Y Average P/S
3.60
Current P/S
3.07
Overvalued
5.30
Undervalued
1.90

Alphio AI Price Scenarios for NEOG

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NEOG

$7.55

Scenario price

B

Base

Base · 50%NEOG

$6.69

Scenario price

B

Bear

Bear · 25%NEOG

$6.11

Scenario price

Whales holding NEOG

G

Gates Capital Management, Inc.

+ HoldingNEOG

-8.65%

3M Return

Events Timeline

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

09:00:00

Stock Futures Point to Lower Open as Tech Stocks Weigh

2026-10-06 (ET)

20:00:00

Nasdaq and S&P 500 Hit Record Highs

16:30:00

Neogen Reports Q1 Revenue of $222.8M, Beating Expectations

News

NEOG FAQ — answered by Alphio AI

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, which reflects strong confidence in future performance. Additionally, the stock has shown a remarkable year-to-date change of +68.71% and a one-year change of +100.51%, indicating robust growth. However, a key risk is the current RSI of 40.44, suggesting that the stock may be approaching oversold territory, which could lead to short-term volatility.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.

Community

More ↗
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading